10 news items
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
TAK
22 Apr 24
the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
TAK
18 Apr 24
and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
TAK
27 Mar 24
options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality- diverse pipeline. Our employees
l45kfnk2khp
TAK
26 Mar 24
partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading
9pm6hzuhfogwz9x42p3vr6dr9 8qxnahf7961l8
TAK
13 Mar 24
the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D
lpryec4epfgeeu7uo7p759eu7p0m z4uuqsqq0pazq2ay37
TAK
26 Feb 24
. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse
kojw2jdo200bwu3uljguylt765wvrv 7g
TAK
26 Feb 24
of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our
to7tn1mxiw8yxe9frb13wqg25ox1o5tv6m38bic9w89pj jk1qwrmw48imy
TAK
13 Feb 24
a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health
- Prev
- 1
- Next